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Abstract  
AIM: The present study investigated the protective effect of the phytoestrogen, genistein (GEN), against (CP)-
induced acute hepatotoxicity in rats.  
MATERIAL AND METHODS: Male adult rats were randomly assigned into five groups. Normal control group 
received the vehicles; CP group received a single dose of CP (200 mg/kg, i.p). The other three groups received 
subcutaneous GEN at doses of 0.5, 1 and 2 mg/kg/day, respectively, for 15 consecutive days prior CP injection. 
Sera and liver tissues were collected forty-eight hours after CP injection for assessment of liver function enzymes 
(ALT and AST) in rat sera, the hepatic oxidative/nitrosative biomarkers (GSH, MDA and NOx), hepatic interleukin-
1β, and myeloperoxidase activity. Immunohistochemistry of cyclooxygenase-2 and histopathological examination 
of liver tissues were also conducted.  
RESULTS: The CP-induced acute liver damage was evidenced by elevated serum ALT and AST accompanied by 
increased hepatic oxidative stress and inflammatory biomarkers. Immunohistochemical outcomes revealed 
hepatic cyclooxygenase-2 expression in CP group with distortion of liver architecture. GEN-pretreatment 
significantly ameliorated the deterioration of liver function and exerted significant anti-oxidant and anti-
inflammatory activity with a marked decline in hepatic cyclooxygenase-2 expression in a dose dependent-manner.  
CONCLUSION: The present study demonstrated that the antioxidant and anti-inflammatory activities of GEN 
might contribute to its protective effects against CP-induced liver damage. 
 
 
 
 
 
 
 
Introduction 
 
Cyclophosphamide (CP) is an 
oxazaphosphorine derivative of the traditional 
alkylating agent nitrogen mustard [1]. 
Cyclophosphamide is widely used in the treatment of 
several human cancers [2] including solid tumours, 
lymphomas and leukaemia [3], as well as many non-
neoplastic diseases, such as systemic lupus 
erythematosus and rheumatoid arthritis [4, 5]. The 
therapeutic dose of CP has been shown to cause liver 
toxicity; which often restricts its clinical use [6-8]. 
Growing evidence suggests that oxidative stress plays 
a major role in CP-induced hepatotoxicity [9, 10] via 
causing severe cellular damage accompanied by lipid 
peroxidation and changes in cellular nucleic acids [11, 
12]. CP is metabolised by the hepatic microsomal 
cytochrome P450 (CYP450), giving rise to 
phosphoramide mustard and acrolein [13]. Acrolein; a 
highly reactive metabolite of CP with short biological 
half-life; inhibits CYP450 by alkylating the reduced 
glutathione (GSH) sulfhydryl groups thus inducing 
oxidative stress and causing hepatotoxicity [14, 15]. 
Furthermore, CP damages mitochondria and impairs 
cellular respiration [16]. Thus it interferes with hepatic 
intracellular oxidant/antioxidant balance leading to 
reactive oxygen species (ROS) accumulation [9]. ROS 
then induces lipid peroxidation and activates multiple 
signalling cytotoxicity pathways including nuclear 
transcription factor kappa-B (NF-κB) and mitogen-
activated protein kinases (MAPKs), thus initiating 
different steps in the inflammatory pathway [17]. Thus, 
introducing some anti-oxidant agents may be useful in 
alleviating the toxic side effect of anti-cancer drugs. 
Earlier studies have shown that some plant extracts 
with antioxidant activity protect against CP 
hepatotoxicity [18-20]. Accordingly, chemotherapeutic-
treatment protocol combined with potent and safe 
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antioxidants could be a desirable tool to mitigate CP-
induced hepatotoxicity. 
Genistein (GEN), a phytoestrogen present in 
soy products, possesses structural similarity to 
estrogen. GEN acts like human estrogen and binds to 
estrogen receptors [21] which justifies its use for 
treatment of symptoms of menopause [22]. Previous 
studies suggested that GEN possesses anti-
osteoporotic, anti-neoplastic, cardio-protective, anti-
proliferative, anti-apoptotic, anti-necrotic, antioxidant 
and anti-inflammatory actions [23].  
It has been well-established the link between 
the estrogenic activity of GEN and its antioxidant 
effect via decreasing oxidative stress as a 
consequence of increased expression of antioxidant 
defence genes [24]. Recently, GEN has been shown 
to improve the endothelium-dependent relaxation in 
insulin-resistant ovariectomized rats with further 
modulation of the elevated blood pressure [25]. 
Previous studies reported GEN-hepatoprotective 
activity against several models of hepatotoxicity [26, 
27].  
Therefore, the current study aims at exploring 
the potential protective effects of GEN against 
cyclophosphamide-induced hepatotoxicity in rats. 
 
 
Materials and Methods 
 
Animals 
Forty adult male Sprague-Dawley rats 
weighing 180-200 g were utilised in the present study. 
Standard food pellets and tap water were supplied ad 
libitum. Animals and food pellets were obtained from 
the animal house colony of the National Research 
Center (NRC, Egypt). The study was conducted by 
ethical procedures and policies outlined in the 
Canadian Council of Animal Care guidelines (NAC 
2011) and was approved by the Medical Research 
Ethics Committee (MREC) of the National Research 
Centre (approval no. 16/434).  
 
Drugs and chemicals 
Genistein (LC Laboratories, Woburn, 
Massachusetts, USA; purity > 99%) and 
cyclophosphamide (CP, Endoxan®, Baxter Oncology 
GmbH, Germany) were used in the study. GEN was 
dissolved in 5 ml DMSO (1.25%) and divided into 
equal aliquots [28]. Every day, an aliquot of the drug 
was freshly diluted by distilled water and injected 
subcutaneously. The concentration was adjusted so 
that each 100 g animal body weight received 0.25 ml, 
0.5 ml and 1 ml for doses 0.5, 1 and 2 mg/kg, 
respectively [29]. CP was injected intraperitoneally in 
a single hepatotoxic dose of 200 mg/kg [7]. All of the 
other chemicals were of highest analytical grade 
available. 
 
Experimental design and treatment 
protocol 
Animals were randomly allocated into five 
groups (8 rats each). Rats of the 1
st
 group received 
subcutaneous injections of the corresponding vehicle 
(DMSO) and served as normal control group. Acute 
hepatotoxicity was induced in the remaining four 
groups by single intraperitoneal injection of 
cyclophosphamide (CP; 200 mg/kg) on the 15
th
 day of 
treatment. Group 2 received only the vehicle (saline) 
subcutaneously for 15 days before CP treatment and 
served as CP control group. Groups 3, 4 and 5 
received genistein (GEN; 0.5, 1 and 2 mg/kg/day, s.c.) 
respectively for 15 days before CP treatment on day 
15. All animals were sacrificed 48 h after CP injection.  
 
Serum biochemical analysis 
Forty-eight hours after CP injection, rats were 
anaesthetised with diethyl ether, and blood samples 
were withdrawn from the retro-orbital venous plexus. 
Collected blood samples were allowed to stand for 10 
min at room temperature then centrifuged at 4
o
C using 
cooling centrifuge (Laborezentrifugen, 2k15, Sigma, 
Germany) at 3000 r.p.m for 10 min and sera were 
separated for the assessment of levels of aspartate 
aminotransferase (AST) and alanine aminotransferase 
(ALT) according to the methods of Reitman and 
Frankel (1957) using commercially available 
colorimetric assay kits (Biodiagnostic, Egypt) [30].  
 
Hepatic Tissue biochemical analysis  
Directly after collecting the last blood sample 
in the experiment, rats were sacrificed by cervical 
dislocation and liver tissues were collected, washed 
with normal saline and then divided into 3 parts: one 
part was homogenized (using MPW–120 
homogenizer, Med instruments, Poland); the 
homogenate was centrifuged using a cooling 
centrifuge (Laborezentrifugen, 2k15, Sigma, 
Germany) at 3000 r.p.m for 10 min; the supernatant 
was assessed for hepatic levels of reduced 
glutathione (GSH), lipid peroxides as 
malondialdehyde (MDA) [32], and nitric oxide (NO) 
metabolites [33]. Moreover, inflammatory markers 
such as myeloperoxidase (MPO) [34], interleukin-1β 
(IL-1β) were assessed using enzyme-linked 
immunosorbent assay (ELISA) kits (Hycult Biotech, 
Netherlands) and (R&D Systems, USA), respectively, 
according to the manufacturer's instructions. 
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Immunohistochemistry of 
Cyclooxygenase-2 (COX-2) 
Liver COX-2 was assessed by 
immunohistochemical staining. Liver sections on 
polylysine-coated slides obtained were fixed in neutral 
buffered formalin, and embedded in paraffin and were 
treated for COX-2 antibodies for immunohistochemical 
analysis. Following deparaffinization and rehydration, 
sections were irradiated in 0.1 mol/L sodium citrate 
buffer [pH 6.0] in a microwave oven [medium low 
temperature] for 20 min. Then the sections were 
exposed to 3% H2O2 for 10 min to bleach endogenous 
per-oxidases, followed by rinsing three times in Tris 
buffer (pH 7.4) for 10 min. Sections were selectively 
incubated under humid conditions using an anti-COX-
2 antibody [1:200; Santacruz Biotechnology, Inc., 
USA] [10].  
 
Histopathological examination  
The other parts of the livers were fixed in 10% 
neutral buffered formalin and embedded in paraffin 
wax. 4 µm thick sections were stained with 
Hematoxylin and Eosin (H&E) and examined using 
binocular Olympus CX31 microscope [35].  
 
Statistical analysis 
All the values are presented as means ± 
standard error of the means (SEM) of eight 
experiments. Comparisons between different groups 
were carried out using one-way analysis of variance 
(ANOVA) followed by Tukey’s multiple comparison 
post hoc tests. The difference was considered 
significant when P ˂ 0.05. GraphPad prism
®
 software 
(version 6 for Windows, San Diego, California, USA) 
was used to carry out these statistical tests.  
 
 
Results 
 
Effects of GEN on serum liver microsomal 
enzymes in CP-induced hepatotoxicity in 
rats 
Cyclophosphamide (CP, 200 mg/kg, i.p.) 
resulted in acute liver damage in rats as evidenced by 
the significant elevation of serum alanine trans-
aminase (ALT) and aspartate transaminase (AST) to 
477% and 285%, respectively, as compared to the 
normal control group. Pretreatment of rats with GEN 
(0.5, 1 or 2 mg/kg/day, s.c.) significantly decreased 
the elevated serum AST and ALT in a dose-
dependent manner as compared to the CP-control 
group. Genistein treatment at 2 mg/kg recorded 
normal levels of ALT and improved both ALT and AST 
significantly compared to the other dose levels (Figure 
1). 
 
Figure 1: Effects of genistein on serum alanine transaminase (ALT) 
and aspartate transaminase (AST) in cyclophosphamide-induced 
hepatotoxicity in rats. Rats of the normal control group received s.c. 
Injections of DMSO. Acute hepatotoxicity was induced in the 
remaining four groups by single intraperitoneal injection of 
cyclophosphamide (CP; 200 mg/kg) on the 15th day of treatment. 
Group 2 received only saline s.c. for 15 days and served as CP 
control group. Groups 3, 4 and 5 received genistein (GEN; 0.5, 1 
and two mg/kg/day, s.c.) respectively for 15 days before CP 
treatment. All animals were sacrificed 48 h after CP injection, blood 
samples were collected, and sera were separated. Data are 
presented as mean ± SEM (n = 8). a, Significantly different from 
Normal control group at p < 0.05 (Tukey's post hoc test). b, 
significantly different from CP control group at p < 0.05 (Tukey's 
post hoc test). c, Significantly different from CP+GEN (0.5 mg/kg) 
group at p < 0.05 (Tukey 's post hoc test). d Significantly different 
from CP+GEN (l mg/kg) group at p < 0.05 (Tukey's post hoc test) 
 
Effects of GEN on hepatic 
oxidative/nitrosative stress parameters in 
CP-induced hepatotoxicity in rats. 
Cyclophosphamide (CP, 200 mg/kg, i.p.) 
resulted in acute liver damage in rats as evidenced by 
a significant decrease in hepatic GSH by 77%, with a 
marked increase in hepatic MDA and NO as 
compared to the normal control group.  
Pretreatment of rats with GEN, at 1 and 2 
mg/kg, significantly elevated the decreased liver GSH 
while GEN at 0.5 mg/kg failed to exert significant 
increase in GSH as compared to the CP-control 
group. On the other hand, GEN-pretreatment (0.5, 1 
and 2 mg/kg/day, s.c.) for 15 days prior CP injection 
significantly reduced the elevation in hepatic MDA and 
NO in a dose-dependent manner compared to the CP-
control group, recording normal levels of NO at GEN 
dose of 2 mg/kg/day with insignificant difference from 
normal control group (Table 1). 
 
Effects of GEN on hepatic inflammatory 
marker (MPO) and the cytokine (IL-1β) in 
CP-induced hepatotoxicity in rats 
Cyclophosphamide (CP, 200 mg/kg, i.p.) 
resulted in acute liver damage in rats as evidenced by 
an increase in hepatic MPO and IL-1β content as 
compared to the normal control group. Pretreatment 
of rats with GEN (0.5, 1 and 2 mg/kg/day, s.c.) for 15 
days prior CP injection significantly reduced the 
elevation in hepatic MPO and IL-1β in a dose-
dependent manner compared to the CP-control group, 
recording normal levels of MPO and IL-1β at GEN 
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dose of 2 mg/kg/day with insignificant difference from 
normal control group (Table 1). 
Table 1: Effects of genistein on reduced hepatic glutathione 
(GSH), malondialdehyde (MDA), nitric oxide (NO) metabolites, 
myeloperoxidase (MPO), and interleukin one beta (Dtp) 
contents in cyclophosphamide-induced hepatotoxicity in rats 
 
Rats of the normal control group received s.c. Injections of DMSO. Acute hepatotoxicity 
was induced in the remaining four groups by single intraperitoneal injection of 
cyclophosphamide (CP; 200 mg/kg) on the 15th day of treatment. Group 2 received only 
saline s.c. for 15 days and served as CP control group. Groups 3, 4 and 5 received 
genistein (GEN; 0.5, 1 and 2 mg/kg/day, s.c.) respectively for 15 days before CP 
treatment. All animals were sacrificed 48 h after CP injection. The livers were removed, 
homogenized, and the homogenate was obtained. Data are presented as mean ± SEM (n 
= 8). a, Significantly different from Normal control group at p < 0.05 (Tukey's post hoc test). 
b, Significantly different from CP control group at p < 0.05 (Tukey's post hoc test). C, 
Significantly different from CP+GEN (0.5 mg/kg) group at p < 0.05 (Tukey's post hoc test). 
d Significantly different from CP+GEN (l mg/kg) group at p < 0.05 (Tukey's post hoc test) 
 
 
Effect of GEN on Cyclooxygenase-2 (COX-
2) expression in liver tissue 
Pretreatment with genistein for 15 days before 
CP injection showed a dose-dependent reduction in 
hepatic COX-2 expression ranging from mild, 
moderate and negative COX-2 immunostaining of the 
kupffer cells and the hepatocytes at 0.5, 1 and 2 
mg/kg of GEN, respectively, compared to CP-treated 
liver tissues.  
 
Figure 2: A. Photomicrograph of liver sections prepared from a 
normal control rat showing negative. COX-2 immunostaining of the 
kupffer cells and the hepatocytes (COX-2 immunohistochemistry 
H&E X 80). B. Photomicrograph of liver sections prepared from a 
cyclophosphamide-control rat showing severe COX-2 
immunostaining of the kupffer cells and the hepatocytes (COX-2 
immunohistochemistry H&E X 80). C. Photomicrograph of liver 
sections prepared from a rat treated with genistein (0.5 mg/kg/day, 
s.c.) for 15 days before CP treatment showing moderate COX-2 
immunostaining of the kupffer cells and the hepatocytes (COX-2 
immunohistochemistry H&E X 80). D. Photomicrograph of liver 
sections prepared from a rat treated with genistein (1 m///lkg/day, 
s.c.) for 15 days before CP treatment showing mild COX-2 
immunostaining of the kupffer cells and the hepatocytes (COX-2 
immunohistochemistry H&E X 80). E. Photomicrograph of liver 
sections prepared from a rat treated with genistein (2 m/l:g/day, 
s.c.) for 15 days before CP treatment showing negative COX-2 
immunostaining of the kupffer cells and the hepatocytes (COX-2 
immunohistochemistry H&E X 80) 
Cyclophosphamide caused severe COX-2 
immunostaining of the kupffer cells and the 
hepatocytes compared to normal tissues (Figure 2). 
 
Effect of GEN on in liver histopathological 
picture 
Cyclophosphamide exerted severe distortion 
in the hepatic architecture showing severe congestion 
and dilatation of the central and portal veins 
associated with degeneration in the hepatocytes 
surrounding the central vein and oedema in the portal 
area after 48 hours of injection (Figure 3). While GEN-
pretreatment restored the histopathological picture of 
the liver causing mild to a moderate improvement 
compared to CP-treated liver tissues (Figure 3). 
 
Figure 3: Photomicrograph of a liver section of a rat from a normal 
control group (H&E X 40) showing no histopathological alteration 
and the normal histological structure of the central vein and 
surrounding hepatocytes were recorded (Figure 3A). 
Photomicrograph of a liver section of a rat from the 
cyclophosphamide-control group (H&E X 40) showing severe 
congestion and dilatation of the central and portal veins associated 
with degeneration in the hepatocytes surrounding the central vein 
and oedema in the portal area (Figure 3B). Photomicrograph of a 
liver section of a rat that received genistein (0.5 mg/kg/day, s.c.) for 
15 days before CP treatment (H&E X 40) showing mild 
improvement in the overall histopathological picture. Inflammatory 
cells infiltration was apparent in the portal area while the 
hepatocytes showed degenerative change (Figure 3C). 
Photomicrograph of a liver section of a rat that received genistein (1 
mg/kg/day, s.c.) for 15 days before CP treatment (H&E X 40) 
showing minimal improvement in the overall histopathological 
picture. Dilatation and congestion in the central veins associated 
with degeneration in the surrounding adjacent hepatocytes were 
apparent (Figure 3D). Photomicrograph of a liver section of a rat 
that received genistein (2 mg/kg/day, s.c.) for 15 days before CP 
treatment (H&E X 40) showing moderate improvement in the overall 
histopathological picture. Congestion in the central and portal veins 
along with degeneration in the surrounding hepatocytes was also 
apparent (Figure 3E) 
 
 
Discussion 
 
Chemotherapy-induced oxidative stress 
causes severe cellular and tissue damage and usually 
results in many undesirable side effects [36]. 
Cyclophosphamide, a widely known chemotherapeutic 
agent used in the treatment of several human 
cancers, is well known to induce prominent oxidative 
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stress in the liver [13]. Even low doses of CP can 
produce significant hepatotoxicity in humans which 
often stands as a barrier against its clinical use [4, 37].  
In the present study, CP-treated animals 
showed significant elevation of liver function enzymes 
AST and ALT, important markers for the evaluation of 
liver injury since their leakage into serum defines the 
severity of liver damage [38]. Liver tissue oxidative 
stress parameters; MDA and NO, inflammatory 
enzymes; MPO and liver tissue cytokine IL-1β were 
significantly elevated while liver tissue GSH content 
was significantly decreased when compared to normal 
counterparts. Cyclophosphamide administration 
exerted severe expression of hepatic cyclooxygenase-
2 (COX-2) as well. Moreover, CP caused severe 
deterioration of the overall histopathological picture of 
the liver tissue when compared to normal control 
group. Our results are in line with previous reports that 
stated severe hepatotoxicity associated with elevated 
AST, ALT [4] and lactate dehydrogenase (LDH) [10, 
39] with a significant elevation in oxidative stress 
marker; MDA and a significant decrease in GSH, 
along with deteriorated histopathological picture in 
CP-treated rats [9]. Linking oxidative stress to 
inflammation, myeloperoxidase (MPO) was found to 
exert a primary role in chronic inflammation [40] and 
demonstrates an essential mechanistic link between 
oxidation and inflammation [41]. Increased levels of 
MPO and the pro-inflammatory cytokine; IL-1β after 
CP administration was reported after 48 hours in the 
present study. In a recent study, COX-2 expression in 
liver of rats received CP was increased along with 
significant elevation in serum ALT, liver NF-κB p65, 
TNF-α, IL-1β, MDA, NO, Bax/Bcl-2 ratio, inducible 
nitric oxide synthetase (iNOS), caspases 3 and 9 
activities while decreased hepatic total antioxidant 
capacity [42]. Furthermore, TNF-α and IL-1β play 
crucial roles in stimulation of iNOS and COX-2 [23, 
43], which further explains the increased levels of NO 
after CP administration. Others reported elevation in 
pro-inflammatory mediators like TNF-α, IL-1β, IL-6 
and COX-2 along with increased ROS, LPO, 
decreased GSH and antioxidant enzymes (SOD, CAT, 
GST, and GSH-Px) in liver tissues of CP-treated 
animals [44]. These further support current data of 
increased oxidation and inflammation in CP 
hepatotoxicity. 
Since its discovery in 1987, genistein has 
been investigated in a myriad of research fields, 
especially after reporting no side effects or toxicity 
with high doses of genistein in vivo [45]. GEN; a 
phytoestrogen found abundantly in soy and widely 
used an alternative to estrogens; possesses immune-
modulatory effects of estrogen without exhibiting its 
side effects [21]. GEN mainly undergoes hepatic 
metabolism through cytochrome P450 system to give 
monohydroxyl and dihydroxyl metabolites [46]. 
Exhibiting well-established antioxidant and anti-
inflammatory properties against different models of 
hepatotoxicity, pretreatment of rats with GEN (0.5, 1 
and 2 mg/kg/day, s.c.) for 15 days significantly 
protected against CP-induced deterioration of liver 
function and showed marked anti-oxidant and anti-
inflammatory properties that were demonstrated by 
the reduction of serum AST and ALT, hepatic MDA, 
NO, MPO and IL-1β while elevation of hepatic GSH 
content when compared to CP group. Previous 
studies revealed the potent hepatoprotective effect of 
GEN through elevation of liver GSH and reduction of 
liver MDA in thioacetamide- [29] and CCl4- [26, 47] 
induced hepatotoxicity. GEN exhibited protective 
effects against oxidative stress hepatic injury as 
manifested by increased activity of hepatic SOD, 
catalase, glutathione peroxidase and reduction of 
MDA level [48, 49]. Meanwhile, GEN exerted 
ameliorative effects on hepatic injury and fibrosis 
induced by chronic alcohol in rats [50]. Some 
researchers attributed the anti-inflammatory effects of 
GEN to its antioxidant effects [51] where significant 
low levels of plasma TNF-α was reported in non-
alcoholic steatohepatitis by GEN antioxidant 
properties [52]. A Recent study revealed protective 
effects of GEN against CP-induced ovarian toxicity by 
mitigating oxidative stress and inflammation through 
elevating GSH, SOD while reducing MDA along with 
modulation of IL-1β and iNOS, respectively [29].  
Moreover, GEN was shown to inhibit NO 
production from activated macrophages by LPS and 
IFN-γ through inhibition of iNOS expression [53] by 
suppression of STAT-1 and NF-κB activation, which 
are important transcription factors for iNOS [54] that 
further supports our current observations. The anti-
inflammatory effects of GEN were demonstrated 
earlier [55], which was in line with current results that 
revealed reduced hepatic levels of MPO and IL-1β 
after CP administration. In a rat model of D-
galactosamine-induced fulminant hepatic failure, GEN 
supplementation exerted an anti-inflammatory activity 
via modulation of iNOS and COX-2, thereby reducing 
NO and prostaglandin-E2 (PGE2) levels, respectively. 
Also, pro-inflammatory cytokines; TNF-α and IL-1β 
are reduced with the suppression of NF-ĸB activation, 
IKKα/β and mitogen-activated protein kinase (MAPK) 
with a significant reduction in the serum AST and ALT 
levels as well as serum and liver tissue MDA 
accompanied by significant elevation of liver tissue 
GSH concentration [23].  
Being contributed to the pathogenesis of 
inflammation-related diseases, a recent study 
demonstrated the relation between COX-2 and IL-1β 
as COX-2 catalyzes the synthesis of PGE2 and 
increases IL-1β by increasing NF-κB activation and 
enhancing caspase-1 activation through triggering 
mitochondrial damage, mitochondrial reactive oxygen 
species production and subsequent release of 
mitochondrial DNA into cytosol via pyrin domain-
containing 3 (NLRP3) inflammasome, a reactive 
oxygen species-sensitive multiprotein complex, that 
regulates IL-1β maturation in the spleen and liver of 
LPS-challenged mice [56]. Hence, linking decreased 
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level of hepatic IL-1β and COX-2 expression by GEN-
pretreatment in a dose-dependent manner in CP-
treated liver tissues, providing a new insight of GEN 
as a potential protective agent in inflammatory liver 
disease. Eventually, GEN caused significant 
improvement of the overall histopathological picture of 
the liver when compared to CP-control group. 
From the current study, it can be concluded 
that GEN possesses potent ameliorative effects 
against hepatotoxic actions of CP from various 
aspects. GEN significantly decreased the elevated 
serum levels of hepatic microsomal enzymes, reduced 
oxidative stress parameters as MDA and NO, 
augmented anti-oxidation via elevating GSH along 
with decreased inflammatory mediators; MPO, IL-1β 
and COX-2 expression. Hence, it may provide 
effective protection against liver damage via anti-
oxidative and anti-inflammatory activities.  
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